Bloodbased monitoring identifies acquired and targetable driver HER2 mutations in endocrineresistant metastatic breast cancer
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
23:20 EDT 16 Jul 2019 |
NEJM
More From BioPortfolio on "Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer"